Investment House LLC Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

Investment House LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 8.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,830 shares of the biopharmaceutical company’s stock after selling 2,372 shares during the period. Investment House LLC’s holdings in Pfizer were worth $772,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of PFE. Trifecta Capital Advisors LLC increased its position in Pfizer by 3.7% during the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 325 shares in the last quarter. Confluence Wealth Services Inc. increased its holdings in shares of Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock valued at $2,158,000 after acquiring an additional 342 shares in the last quarter. Carr Financial Group Corp raised its position in shares of Pfizer by 3.3% in the 3rd quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 355 shares during the last quarter. Caldwell Sutter Capital Inc. boosted its stake in Pfizer by 0.5% in the 3rd quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after purchasing an additional 364 shares in the last quarter. Finally, Bill Few Associates Inc. grew its position in Pfizer by 0.5% during the 3rd quarter. Bill Few Associates Inc. now owns 80,820 shares of the biopharmaceutical company’s stock worth $2,681,000 after purchasing an additional 368 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Guggenheim started coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target for the company. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Trading Up 0.1 %

Shares of PFE opened at $25.67 on Tuesday. The firm’s fifty day moving average is $26.92 and its two-hundred day moving average is $28.31. The stock has a market cap of $145.36 billion, a PE ratio of 71.25, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.14 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.54%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.